Headlines about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.5321947819778 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have effected Accern’s analysis:
- IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces … – ForexTV.com (forextv.com)
- Foundation Medicine, Inc. (NASDAQ:FMI) Closed -5.1% Below Its 50 Day Moving Average – Modern Readers (modernreaders.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Foundation Medicine, Inc. of a Class Action … – GlobeNewswire (press release) (globenewswire.com)
- FOUNDATION MEDICINE SHAREHOLDER ALERT BY FORMER … – PR Newswire (press release) (prnewswire.com)
- IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Reminds Investors with Losses to Contact the Firm (finance.yahoo.com)
A number of equities research analysts recently commented on FMI shares. BTIG Research upgraded Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Monday, May 15th. BidaskClub upgraded Foundation Medicine from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, ValuEngine upgraded Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $29.50.
Shares of Foundation Medicine (FMI) traded up 1.25% during midday trading on Friday, reaching $36.55. The company’s stock had a trading volume of 243,622 shares. Foundation Medicine has a one year low of $17.10 and a one year high of $43.15. The firm’s market cap is $1.32 billion. The stock’s 50 day moving average price is $37.92 and its 200 day moving average price is $34.18.
Foundation Medicine (NASDAQ:FMI) last announced its earnings results on Tuesday, August 1st. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by $0.16. The firm had revenue of $35 million during the quarter, compared to analysts’ expectations of $34.94 million. Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.84) EPS. Analysts predict that Foundation Medicine will post ($4.64) earnings per share for the current year.
In other news, insider David Daly sold 46,872 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $39.50, for a total transaction of $1,851,444.00. Following the sale, the insider now owns 163,133 shares of the company’s stock, valued at $6,443,753.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jason Ryan sold 5,573 shares of the company’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $40.00, for a total value of $222,920.00. Following the sale, the chief financial officer now directly owns 78,405 shares in the company, valued at approximately $3,136,200. The disclosure for this sale can be found here. In the last three months, insiders sold 188,680 shares of company stock worth $7,367,362. 2.70% of the stock is owned by corporate insiders.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.